Loading
Virus-based Gene Therapy Research / CRISPR and Genetic Engineering · Journal article
Frontiers in Genome Editing · September 10, 2026
A consensus or society position rather than new primary data.
This is a narrative review of CRISPR/Cas9-based gene therapy strategies for hemophilia, synthesizing the current landscape of AAV vector delivery and gene editing approaches. The article outlines approved therapies, ongoing clinical trials, and technical advantages of site-specific integration over random gene insertion, but does not report original clinical efficacy data or comparative outcomes.
Journal article. Hemophilia patients (hemophilia A and B), treated via hepatocyte gene therapy approaches..
Several AAV-based gene addition therapies have been approved for hemophilia B and hemophilia A, with dozens of similar AAV-based clinical trials underway. CRISPR/Cas9-mediated transgene integration enables site-specific, targeted genomic integration rather than random integration, providing critical advantages over regular gene insertion therapy. One prominent ongoing clinical trial for hemophilia B is designed to insert the human Factor IX gene into hepatocytes using AAV-CRISPR/Cas9-mediated knock-in.
No original clinical trial results, efficacy data, safety outcomes, or comparative effect sizes reported. No specific figures on treatment durability, immunogenicity, or adverse event rates from clinical studies.
This review offers clinicians and researchers an overview of emerging CRISPR-based treatment modalities for hemophilia and highlights the rationale for site-specific gene editing over conventional gene addition. However, as a review article without novel clinical efficacy data, it should be read as a state-of-the-field synthesis rather than evidence of proven clinical benefit.
A narrative review article synthesizing current knowledge and future directions in CRISPR-based gene therapy for hemophilia, without reporting original empirical findings or clinical trial results.
This review offers clinicians and researchers an overview of emerging CRISPR-based treatment modalities for hemophilia and highlights the rationale for site-specific gene editing over conventional gene addition. However, as a review article without novel clinical efficacy data, it should be read as a state-of-the-field synthesis rather than evidence of proven clinical benefit.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Hemophilia is an X-linked hereditary bleeding disorder caused by loss-of-function mutations in the genes encoding coagulation factors, leading to excessive bleeding and potentially being life-threatening. Currently, regular treatment for hemophilia is the infusion of recombinant blood coagulation factors. This approach is not only costly but can also give rise to complications such as the development of neutralizing antibodies (Nabs), which impede the therapeutic outcome. Hemophilia is a monogenic disease, making gene therapy a promising curative measure that includes gene addition and gene editing approaches. Adeno-associated virus (AAV) vectors have gained massive attention as the premier delivery vehicle for clinical gene therapy due to their diverse tissue tropisms dictated by the natural and engineered AAV capsids, their excellent safety profile since AAVs do not cause any known human diseases, low immunogenicity, and long-lasting gene expression. Several AAV-based gene addition therapies have been approved for hemophilia B and hemophilia A, and dozens of similar AAV-based clinical trials are underway. Gene editing technologies, like Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), have shown immense potential in the treatment of genetic diseases. CRISPR/Cas9-mediated transgene integration provides critical advantages over regular gene insertion therapy by enabling site-specific, targeted genomic integration rather than random integration. Clinical trials focusing on AAV-CRISPR/Cas9-mediated knock-in of human genes represent the frontier of in vivo genetic medicine, and one such prominent ongoing clinical trial for hemophilia B is designed to insert the human Factor IX gene into hepatocytes. This review outlines recent advances and feasible strategies of CRISPR/Cas9-based genome editing for hemophilia therapy, highlights the potential applications of next-generation gene editing and vector delivery technologies, and offers new insights for the advantages, limitations, and future directions for these novel treatment modalities.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.